secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001493152-24-030764
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma Q2 net loss $4.96M; LP-300 Harmonic trial 86% CBR
----------------------------------------------------------------

- Net loss of $4.96M ($0.46/shr) for Q2 2024 vs $4.75M ($0.44/shr) a year ago; cash $33.3M at June 30.
- LP-300 Harmonic Phase 2 lead-in (7 pts): 86% clinical benefit rate, 43% objective response rate, no dose-limiting toxicities.
- LP-184 Phase 1A: 7 cohorts dosed, no DLTs; LP-284 third cohort dosing, no DLTs; both on track.
- RADR platform collaboration with Oregon Therapeutics for XCE853; Starlight Therapeutics advancing STAR-001 for recurrent GBM.
- Japanese patent issued for LP-284; Webinar Wednesdays launched for AI and oncology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000149315224030764/0001493152-24-030764-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000149315224030764/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-030764

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer